Correction to ‘Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective’

Ali NH, Al-Kuraishy HM, Al-Gareeb AI, et al. Neprilysin inhibitors and risk of Alzheimer's disease: a future perspective. J Cell Mol Med. 2024;28:e17993. doi:10.1111/jcmm.17993

In Introduction section, the sentence ‘AD is the most common type of dementia, accounting for about 70% of all dementia types’.¹ is incorrect. The sentence should have read: ‘AD is the most common type of dementia, accounting for about 60% to 80% of all dementia types’.^1,149

In Introduction section, the sentence ‘AD is the seventh leading cause of death in the United States, affecting 50 million people globally.³ Approximately 6% of the general population is affected, whereas more than 65% of affected cases are women; nonetheless, 10% of early-onset dementia affecting people aged 30–60 is attributed to AD’.³ is incorrect. The sentence should have read: ‘The global incidence of all-cause dementia is projected to rise from 50 million in 2010 to 113 million by 2050.³ Currently, over 55 million people suffer from AD, which ranks as the seventh leading cause of death in the United States.¹⁵⁰ Additionally, women constitute over 65% of those affected by AD in the United States.¹⁵¹ Nonetheless, 10% of early-onset dementia affecting people aged 30–60 is attributed to AD’.³

In the section 3 NEP INHIBITORS IN AD, the sentence ‘Sacubitril was the first NEP inhibitor approved in 2015 to manage heart failure’.⁴⁰ is incorrect. The sentence should have read: ‘Sacubitril was the first NEP inhibitor approved in 2015 to manage heart failure’.^40,152

Finally in Table 2 for the Bavishi et al.⁴³ the study type ‘Experimental study’ is incorrect. The correct is ‘Review’.

New References

(149) (2023), 2023 Alzheimer's disease facts and figures. Alzheimer's Dement. 19: 1598-1695. doi:10.1002/alz.13016

(150) 2024 Alzheimer's disease facts and figures. 1/6/2024. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf

(151) Rabinovici GD. Late-onset Alzheimer Disease. Continuum (Minneap Minn). 2019;25(1):14-33. doi: 10.1212/CON.0000000000000700. PMID: 30707185; PMCID: PMC6548536.

(152) Fala L. Entresto (Sacubitril/Valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. Am Health Drug Benefits. 2015;8(6):330-334. PMID: 26557227; PMCID: PMC4636283.

We apologize for this error.